AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Business Wire•21/10/2026•07:00 ET
0
Key Highlights
- ➤AN2 to present Phase 2 epetraborole trial design for phlebotomy-dependent polycythemia vera
- ➤Poster presentation scheduled October 29, 2026, at international MPN congress
- ➤AN2 expects three Phase 2 studies to be active in 2026
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18(th) International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18(th) International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York.
Get started
Create a free account to read the full story.